Research programme: AMPA antagonists - Egis Pharmaceuticals

Drug Profile

Research programme: AMPA antagonists - Egis Pharmaceuticals

Alternative Names: EGIS-10608; EGIS-10609; EGIS-10733; EGIS-11229

Latest Information Update: 14 Sep 2010

Price : $50

At a glance

  • Originator Egis Pharmaceuticals
  • Class Benzodiazepines
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Epilepsy; Neuroprotection; Stroke

Most Recent Events

  • 17 Oct 2007 Pharmacodynamics data from preclinical trials in Neurological disorders presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)
  • 21 Sep 2005 Preclinical trials in Stroke in Hungary (unspecified route)
  • 21 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top